Given the accumulating evidence supporting the application of GLP1R agonists for the treatment of other disease states, including other metabolic diseases and numerous neurological disorders [64] via mechanisms involving autophagy [61,65,66], these findings could have implications beyond the treatment of T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.